Biogen, Eisai sink as much-awaited Alzheimer’s results raise more questions

The drug, dubbed BAN2401, slowed declines associated with Alzheimer’s disease by 30 percent at its highest dose in the trial, compared with placebo, after 18 months.

from Health Care https://ift.tt/2OjjhuH